Rethinking Psychedelic REMS
Study at a glance
AI-extracted from the abstract| Characteristics | Theoretical or philosophical paper |
|---|---|
| Key points | Argues that current FDA REMS requirements for psychedelic-assisted therapies, illustrated by Spravato's clinic-only, every-use supervision model, limit access and increase costs even though adverse events cluster early in treatment. Proposes a gradual release REMS with intensive initial oversight followed by take-home dosing, telehealth supervision, provider certification, and patient registries, which the authors contend would meet statutory requirements that safety measures be necessary, proportionate, and not unduly burdensome. |
Abstract
FDA REMS and ETASU for psychedelic therapy—psilocybin, MDMA, and Spravato (esketamine)—can enhance safety yet impose clinic-only administration that limits access. Using Spravato’s REMS as precedent, this Article shows how “every-use” in-person supervision and limited distribution increase cost and strain providers even as adverse events cluster early in treatment. It proposes a patient-centered gradual release REMS: intensive oversight at initiation then calibrated step-down via take-home dosing, telehealth supervision, provider certification, and patient registries that generate real-world evidence. The model aligns with §505-1 and 21 U.S.C. § 355-1, which require ETASU to be necessary, proportionate to risk, and not unduly burdensome. It details REMS modification and burden analysis, sponsor–FDA negotiation with CDER/DRISK, diversion and misconduct safeguards, emergency protocols, and payer coverage considerations. Comparisons to COVID-era methadone take-home flexibilities and graduated licensing in U.S. skydiving illustrate how staged privileges can preserve safety while expanding equitable access. The Article offers concrete levers for REMS assessment reports, postmarket commitments, and data capture to support iterative ETASU updates, and maps an implementation path that maintains safety, reduces cost, and improves health-system fit for psychedelic-assisted psychotherapy.